| Data | Hora | Fonte | Título | Código | Companhia |
| 07/12/2009 | 13:00 | Business Wire | Allos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Tre... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/12/2009 | 11:41 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/12/2009 | 13:00 | Business Wire | Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN™ at 51st ASH Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/12/2009 | 11:00 | Business Wire | Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/12/2009 | 11:00 | Business Wire | Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematolo... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 30/11/2009 | 11:00 | Business Wire | Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 23/11/2009 | 09:38 | Marketwired | Ridgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn En | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/11/2009 | 11:00 | Business Wire | Allos Therapeutics Announces New Data on FOLOTYN™ to be Presented at the American Society of Hematology Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/11/2009 | 09:54 | Marketwired | AnalystChoice.com Provides Analytical Coverage on ELNK, NWSA, NTAP, ALTH, HANS and BPOP | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/11/2009 | 12:51 | Business Wire | Allos Therapeutics to Present at Upcoming Conferences in November | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/11/2009 | 19:11 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/11/2009 | 19:01 | Business Wire | Allos Therapeutics Reports Third Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/11/2009 | 08:12 | Marketwired | Global Market Perspective Review on ALTH, CINF, ALKS, DBRN, APOL and INFY from TheFortuneFinancial.com | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 26/10/2009 | 10:00 | Business Wire | Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 22/10/2009 | 08:57 | Marketwired | BenchmarkJournal.com Provides Sector & Company Analysis on OMC, PSE, PWR, ALTH, NWSA and ELNK | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 13/10/2009 | 17:05 | Business Wire | Allos Therapeutics Announces Closing of Public Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 13/10/2009 | 07:40 | Marketwired | ELNK, HERO, ABAT, NTAP, DBRN and ALTH Receives Analytical Coverage from WallStSense.com | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/10/2009 | 18:08 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/10/2009 | 07:19 | Edgar (US Regulatory) | Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/10/2009 | 07:14 | Business Wire | Allos Therapeutics Announces Pricing of Public Offering of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/10/2009 | 17:01 | Business Wire | Allos Therapeutics Announces Proposed Public Offering of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/10/2009 | 08:00 | Business Wire | Allos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/10/2009 | 18:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/10/2009 | 07:36 | Marketwired | RothmanResearch.com Stock Review for SCG, CA, NE, MKC, COL and ALTH | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 25/09/2009 | 08:00 | Business Wire | Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/09/2009 | 17:15 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/09/2009 | 19:09 | Business Wire | Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN™ (pralatrexate) for the Trea... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/09/2009 | 07:00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/09/2009 | 10:05 | Edgar (US Regulatory) | Post-Effective Amendment to Registration Statement (POS AM) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/09/2009 | 09:00 | Business Wire | Allos Therapeutics to Hold Post Advisory Committee Conference Call | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |